there for humanity.

SIBO/IMO (Small Intestinal Bacterial Overgrowth/Intestinal Methanogen Overgrowth) is characterized by an overgrowth of bacteria in the small intestine, which can cause severe bloating, digestive issues, and inflammatory processes in the body, potentially damaging the intestinal lining. The release of toxins and gas production by these bacteria places a heavy burden on the immune system and liver, affecting various regulatory mechanisms and functions of the body. Additionally, those affected experience a significant reduction in their quality of life and often face high psychological stress, which may manifest as anxiety, depression, and exhaustion.

Depending on the severity, intensive, mostly alternative therapies are often required, which can be lengthy and challenging, with a high relapse rate.

In Europe, targeted research on SIBO/IMO is lacking, and therapy recommendations are largely based on research from the US and Australia. Despite evidence that it accounts for around 70% of cases diagnosed as irritable bowel syndrome, SIBO/IMO receives insufficient attention in society. Currently, medical access to the small intestine remains difficult ("black box"), and conventional treatments are mostly limited to antibiotics, which, over the long term, offer little sustainable benefit and can promote an unhealthy microbial environment. Many sufferers remain silent, feel dismissed by doctors, and struggle to find help for their condition.